A brief elevation of serum amyloid A is suffi cient to increase atherosclerosis

Journal of Lipid Research

Volumn 56, Issue 2, 2015, Pages 286-293

  Thompson, Joel C ^a,b   Jayne, Colton ^a   Thompson, Jennifer ^a   Wilson, Patricia G ^a,e   Yoder, Meghan H ^a,d   Webb, Nancy ^b,c   Tannock, Lisa R ^a,b,c  

^a Department of Internal Medicine   (United States)

^b Division of Nutritional Sciences   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Apolipoproteins; Cardiovascular Disease; Extracellular Matrix; Free Form: Biglycan; Lipoproteins; Proteoglycans; Transforming Growth Factor Beta; Vascular Biology

Indexed keywords

AMYLOID A PROTEIN; BIGLYCAN; LOW DENSITY LIPOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; APOLIPOPROTEIN E; HOMEODOMAIN PROTEIN; PROTEOGLYCAN; RAG-1 PROTEIN; SERUM AMYLOID A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DISEASE CARRIER; DISEASE COURSE; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; RISK FACTOR; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CELL CULTURE; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HOMEODOMAIN PROTEINS; MALE; MICE; MICE, KNOCKOUT; PROTEOGLYCANS; SERUM AMYLOID A PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921951426     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M054015     Document Type: Article

References (41)

1. Uhlar, C. M., C. J. Burgess, P. M. Sharp, and A. S. Whitehead. 1994 . Evolution of the serum amyloid A (SAA) protein superfamily. Genomics. 19 : 228-235
2. Meek, R. L., S. Urieli-Shoval, and E. P. Benditt. 1994. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl. Acad. Sci. USA. 91 : 3186-3190
3. Coetzee, G. A., A. F. Strachan, D. R. Van Der Westhuyzen, H. C. Hoppe, M. S. Jeenah, and F. C. De Beer. 1986. Serum amyloid A-containing human high Density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261 : 9644-9651
4. Leinonen, E., E. Hurt-Camejo, O. Wiklund, L. M. Hulten, A. Hiukka, and M. R. Taskinen. 2003. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 166 : 387-394
5. O'Brien, K. D., B. J. Brehm, R. J. Seeley, J. Bean, M. H. Wener, S. Daniels, and D. A. D'Alessio. 2005. Diet-induced weight loss is associated with Decreases in plasma serum amyloid A and C-reactive protein inDepenDent of dietary macronutrient composition in obese subjects. J. Clin. Endocrinol. Metab. 90 : 2244-2249
6. Johnson, B. D., K. E. Kip, O. C. Marroquin, P. M. Ridker, S. F. Kelsey, L. J. Shaw, C. J. Pepine, B. Sharaf, C. N. Bairey Merz, G. Sopko, et al. 2004. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 109 : 726-732
7. Lee, H. Y., S. D. Kim, J. W. Shim, S. Y. Lee, H. Lee, K. H. Cho, J. Yun, and Y. S. Bae. 2008. Serum amyloid A induces CCL2 production via formyl peptiDe receptor-like 1-mediated signaling in human monocytes. J. Immunol. 181 : 4332-4339
8. Lee, H. Y., S. D. Kim, S. H. Baek, J. H. Choi, K. H. Cho, B. A. Zabel , and Y. S. Bae. 2013. Serum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-Density lipoprotein receptor 1 upregulation. Biochem. Biophys. Res. Commun. 433 : 18-23
9. Badolato, R., J. M. Wang, W. J. Murphy, A. R. Lloyd, D. F. Michiel , L. L. Bausserman, D. J. Kelvin, and J. J. Oppenheim. 1994. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infi ltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 180 : 203-209
10. Chiba, T., M. Y. Chang, S. Wang, T. N. Wight, T. S. McMillen, J. F. Oram, T. Vaisar, J. W. Heinecke, F. C. De Beer, M. C. De Beer, et al . 2011. Serum amyloid A facilitates the binding of high-Density lipoprotein from mice injected with lipopolysacchariDe to vascular proteoglycans. Arterioscler. Thromb. Vasc. Biol. 31 : 1326-1332
11. O'Brien, K. D., T. O. McDonald, V. Kunjathoor, K. Eng, E. A. Knopp, K. Lewis, R. Lopez, E. A. Kirk, A. Chait, T. N. Wight, et al . 2005. Serum amyloid A and lipoprotein retention in murine moDels of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25 : 785-790
12. Dong, Z., T. Wu, W. Qin, C. An, Z. Wang, M. Zhang, Y. Zhang, C. Zhang, and F. An. 2011. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-Defi cient mice. Mol. Med. 17 : 1357-1364
13. Williams, K. J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15 : 551-561
14. O'Brien, K. D., K. L. Olin, C. E. Alpers, W. Chiu, M. Ferguson, K. Hudkins, T. N. Wight, and A. Chait. 1998. Comparison of apolipoprotein and proteoglycan Deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation . 98 : 519-527
15. Little, P. J., N. Osman, and K. D. O'Brien. 2008. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr. Opin. Lipidol. 19 : 448-454
16. Williams, K. J., and I. Tabas. 1998. The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol. 9 : 471-474
17. Wilson, P. G., J. C. Thompson, N. R. Webb, F. C. De Beer, V. L. King, and L. R. Tannock. 2008. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-Atherogenic manner. Am. J. Pathol. 173 : 1902-1910
18. Coca, S. G., B. Yusuf, M. G. Shlipak, A. X. Garg, and C. R. Parikh . 2009. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-Analysis. Am. J. Kidney Dis. 53 : 961-973
19. Quartin, A. A., R. M. Schein, D. H. Kett, and P. N. Peduzzi ; for the Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. 1997. MagnituDe and duration of the effect of sepsis on survival. J. Am. Med. Assoc. 277 : 1058-1063
20. Koivula, I., M. Sten, and P. H. Makela. 1999. Prognosis after community-Acquired pneumonia in the elDerly: a population-based 12-year follow-up study. Arch. Intern. Med. 159 : 1550-1555
21. Kim, M. H., M. C. De Beer, J. M. Wroblewski, N. R. Webb, and F. C. De Beer. 2013. SAA does not induce cytokine production in physiological conditions. Cytokine. 61 : 506-512
22. Boyanovsky, B. B., D. R. Van Der Westhuyzen, and N. R. Webb . 2005. Group V secretory phospholipase A2-modifi ed low Density lipoprotein promotes foam cell formation by a SR-A-And CD36-inDepenDent process that involves cellular proteoglycans. J. Biol. Chem. 280 : 32746-32752
23. Tang, T., P. G. Wilson, J. C. Thompson, C. Nelson, M. H. YoDer , and L. R. Tannock. 2013. Prevention of TGFbeta induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr /mice. J. Lipid Res. 54 : 2255-2264
24. Thompson, J. C., T. Tang, P. G. Wilson, M. H. YoDer, and L. R. Tannock. 2014. Increased atherosclerosis in mice with increased vascular biglycan content. Atherosclerosis. 235 : 71-75
25. Borén, J., K. Olin, I. Lee, A. Chait, T. N. Wight, and T. L. Innerarity . 1998. IDentifi cation of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Invest. 101 : 2658-2664
26. Vikramadithyan, R. K., Y. Kako, G. Chen, Y. Hu, E. Arikawa-Hirasawa, Y. Yamada, and I. J. Goldberg. 2004. Atherosclerosis in perlecan heterozygous mice. J. Lipid Res. 45 : 1806-1812
27. De Beer, M. C., J. M. Wroblewski, V. P. Noffsinger, A. Ji, J. M. Meyer , D. R. Van Der Westhuyzen, F. C. De Beer, and N. R. Webb. 2013 . The impairment of macrophage-to-feces reverse cholesterol transport during infl ammation does not Depend on serum amyloid A. J. Lipids. 2013 : 283486
28. Tam, S. P., A. Flexman, J. Hulme, and R. Kisilevsky. 2002. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J. Lipid Res. 43 : 1410-1420
29. Kannel, W. B., and D. L. McGee. 1979. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 2 : 120-126
30. Rabkin, S. W., F. A. Mathewson, and P. H. Hsu. 1977. Relation of body weight to Development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am. J. Cardiol. 39 : 452-458
31. Reardon, C. A., L. Blachowicz, T. White, V. Cabana, Y. Wang , J. Lukens, J. Bluestone, and G. S. Getz. 2001. Effect of immune Defi ciency on lipoproteins and atherosclerosis in male apolipoprotein E-Defi cient mice. Arterioscler. Thromb. Vasc. Biol. 21 : 1011-1016
32. Dansky, H. M., S. A. Charlton, M. M. Harper, and J. D. Smith. 1997 . T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-Defi cient mouse. Proc. Natl. Acad. Sci. USA. 94 : 4642-4646
33. Mallat, Z., A. Gojova, C. Marchiol-Fournigault, B. Esposito, C. Kamate, R. Merval, D. FraDelizi, and A. Tedgui. 2001. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89 : 930-934
34. Lutgens, E., M. Gijbels, M. Smook, P. Heeringa, P. Gotwals, V. E. Koteliansky, and M. J. Daemen. 2002. Transforming growth factor-beta mediates balance between infl ammation and fi brosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22 : 975-982
35. De Beer, M. C., J. M. Wroblewski, V. P. Noffsinger, D. L. Rateri, D. A. Howatt, A. Balakrishnan, A. Ji, P. Shridas, J. C. Thompson, D. R. Van Der Westhuyzen, et al. 2014. Defi ciency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-Defi cient mice. Arterioscler. Thromb. Vasc. Biol. 34 : 255-261
36. Skalén, K., M. Gustafsson, E. K. Rydberg, L. M. Hulten, O. Wiklund , T. L. Innerarity, and J. Boren. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 417 : 750-754
37. Gustafsson, M., M. Levin, K. Skalén, J. Perman, V. FriDen, P. Jirholt , S. O. Olofsson, S. Fazio, M. F. Linton, C. F. Semenkovich, et al . 2007. Retention of low-Density lipoprotein in atherosclerotic lesions of the mouse: eviDence for a role of lipoprotein lipase. Circ. Res. 101 : 777-783
38. Danaei, G., M. M. Finucane, Y. Lu, G. M. Singh, M. J. Cowan, C. J. Paciorek, J. K. Lin, F. Farzadfar, Y.-H. Khang, G. A. Stevens, et al . National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epiDemiological studies with 370 country-years and 27 million participants. Lancet. 378 : 31-40
39. Finucane, M. M., G. A. Stevens, M. J. Cowan, G. Danaei, J. K. Lin, C. J. Paciorek, G. M. Singh, H. R. Gutierrez, Y. Lu, A. N. Bahalim , et al. 2011. National, regional, and global trends in body-mass inDex since 1980: systematic analysis of health examination surveys and epiDemiological studies with 960 country-years and 91 million participants. Lancet. 377 : 557-567
40. Ridker, P. M., N. Rifai, M. A. Pfeffer, F. M. Sacks, L. A. Moye, S. Goldman, G. C. Flaker, and E. Braunwald ; for the Cholesterol, and Recurrent Events (CARE) Investigators. 1998. Infl ammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98 : 839-844
41. El Kebir, D., L. Jozsef, T. Khreiss, W. Pan, N. A. Petasis, C. N. Serhan, and J. G. Filep. 2007. Aspirin-triggered lipoxins overriDe the apoptosis-Delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of infl ammation. J. Immunol. 179 : 616-622